When exploring Alzheimer's disease research, the systematic study of the causes, progression, and treatment of Alzheimer's disease. Also known as Alzheimer research, it draws on neurology, genetics, and drug development to slow or reverse cognitive decline. This field pulls together labs, hospitals, and biotech firms, all chasing the same goal: a healthier brain.
One of the biggest bridges in the work is the link between beta‑amyloid, protein fragments that clump into plaques in the brain and the memory loss seen in patients. Researchers measure plaque load with PET scans, then test medicines that either stop plaque formation or clear existing deposits. Alzheimer's disease research also follows the other major culprit: tau protein, the tangled intracellular protein that disrupts neuron function. Studies show that tau pathology often spreads after amyloid accumulation, so many trials now target both proteins together. By pairing biomarker data with clinical outcomes, scientists can tell if a drug truly changes the disease course.
Every new drug must pass through clinical trials, controlled studies that assess safety and efficacy in humans. Phase III trials for anti‑amyloid antibodies have shown modest slowing of cognitive decline, while anti‑tau agents are entering late‑stage testing. Trial designs now incorporate adaptive protocols, allowing researchers to modify dosages or add arms based on early results. This flexibility speeds up decision‑making and reduces the number of participants exposed to ineffective treatments.
Beyond drugs, the research agenda embraces dementia biomarkers, objective measures such as fluid proteins, imaging markers, and genetic risk scores. Biomarkers help identify people at risk before symptoms appear, opening a window for preventive strategies. Lifestyle interventions—exercise, diet, and cognitive training—are being tested alongside pharmacology to see if a combined approach offers greater protection. The end goal is a toolbox where doctors can match a patient’s biomarker profile with the most promising therapy.
Below you’ll find a curated list of articles that break down these topics in detail. From deep dives into specific drug comparisons to practical guides on navigating clinical study enrollment, the collection offers both scientific depth and actionable advice for anyone following the fast‑moving world of Alzheimer’s disease research.
Discover why keeping up with Alzheimer's research matters, recent breakthroughs, approved therapies, diagnostics, and how to stay informed for better care.